Literature DB >> 16091228

Drug interactions with antiretrovirals.

Linda M Catanzaro1, Judianne C Slish, Robert DiCenzo, Gene D Morse.   

Abstract

The recent development of new antiretroviral drugs, along with the evolution in clinical practice guidelines that include the recommendation of the use of three- to four-drug combination regimens for achieving optimal suppression of viral replication, has focused clinicians on the relevance of drug-drug interactions in the chronic care of HIV-infected individuals. However, the routine clinical management of drug interactions is complicated by our expanding knowledge of the physiologic mechanisms underlying pharmacokinetic interactions, particularly as they relate to drug transport and tissue distribution (eg, P-glycoprotein) and biotransformation (hepatic cytochrome p450 mono-oxygenase induction and inhibition). This review provides an updated summary of key drug interactions that have been reported since its initial publication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16091228     DOI: 10.1007/s11904-004-0013-z

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  36 in total

1.  Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.

Authors:  E Ribera; L Pou; R M Lopez; M Crespo; V Falco; I Ocaña; I Ruiz; A Pahissa
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-15       Impact factor: 3.731

Review 2.  Didanosine: an updated review of its use in HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.

Authors:  J Feinberg
Journal:  AIDS Clin Care       Date:  2003-11

4.  Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.

Authors:  Stéphanie Basso; Caroline Solas; Anne-Marie Quinson; Isabelle Ravaux; Isabelle Poizot-Martin; J Bacconier; Alain Durand; Bruno Lacarelle
Journal:  J Acquir Immune Defic Syndr       Date:  2002-09-01       Impact factor: 3.731

5.  The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.

Authors:  S M Clarke; F M Mulcahy; J Tjia; H E Reynolds; S E Gibbons; M G Barry; D J Back
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

6.  Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.

Authors:  B M Sadler; P J Piliero; S L Preston; P P Lloyd; Y Lou; D S Stein
Journal:  AIDS       Date:  2001-05-25       Impact factor: 4.177

7.  Interaction of methadone with didanosine and stavudine.

Authors:  P M Rainey; G Friedland; E F McCance-Katz; L Andrews; S M Mitchell; C Charles; P Jatlow
Journal:  J Acquir Immune Defic Syndr       Date:  2000-07-01       Impact factor: 3.731

8.  Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.

Authors:  K T Olkkola; V J Palkama; P J Neuvonen
Journal:  Anesthesiology       Date:  1999-09       Impact factor: 7.892

9.  Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Authors:  A Hsu; G R Granneman; G Cao; L Carothers; A Japour; T El-Shourbagy; S Dennis; J Berg; K Erdman; J M Leonard; E Sun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

Authors:  Marc Pfister; Line Labbé; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more
  4 in total

Review 1.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

2.  Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Authors:  Qing Ma; Barry S Zingman; Amneris E Luque; Margaret A Fischl; Barbara M Gripshover; Charles S Venuto; Robin DiFrancesco; Alan Forrest; Gene D Morse
Journal:  Ther Drug Monit       Date:  2011-06       Impact factor: 3.681

3.  HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs.

Authors:  Max von Kleist; Stephan Menz; Hartmut Stocker; Keikawus Arasteh; Christof Schütte; Wilhelm Huisinga
Journal:  PLoS One       Date:  2011-03-24       Impact factor: 3.240

4.  Optimal timing and duration of induction therapy for HIV-1 infection.

Authors:  Marcel E Curlin; Shyamala Iyer; John E Mittler
Journal:  PLoS Comput Biol       Date:  2007-07       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.